Chiasma, Inc. clinical trials
Acquired by Chiesi Farmaceutici S.p.A., Apr 12, 2023 · source ↗
The registry lists 3 studies whose lead sponsor is Chiasma, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 22, 2022.
Before and after it joined Chiesi Farmaceutici S.p.A.
- First submitted before Chiasma, Inc. became part of Chiesi Farmaceutici S.p.A.
- 3
- First submitted after Chiasma, Inc. became part of Chiesi Farmaceutici S.p.A.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Chiasma, Inc.3 studies
Something wrong with this grouping? Tell us on the Chiesi Farmaceutici S.p.A. page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Chiesi Farmaceutici S.p.A. studies →
- Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in AcromegalyCompletedNCT02685709Phase 3
Sponsor listed in the registry: Chiasma, Inc. · First submitted before Chiasma, Inc. became part of Chiesi Farmaceutici S.p.A.
- Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in AcromegalyStatus unknownNCT03252353Phase 3
Sponsor listed in the registry: Chiasma, Inc. · First submitted before Chiasma, Inc. became part of Chiesi Farmaceutici S.p.A.
- Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for AcromegalyCompletedNCT01412424Phase 3
Sponsor listed in the registry: Chiasma, Inc. · First submitted before Chiasma, Inc. became part of Chiesi Farmaceutici S.p.A.